World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat

Hidekazu Suzuki, Hideki Mori

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Helicobacter pylori-associated gastritis leads to the development of gastric cancer. Kyoto global consensus report on H. pylori gastritis recommended H. pylori eradication therapy to prevent gastric cancer. To manage H. pylori infection, it is important to choose the appropriate regimen considering regional differences in resistance to clarithromycin and metronidazole. Quinolones and rifabutin-containing regimens are useful as third- and fourth-line rescue therapies.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalJournal of Gastroenterology
DOIs
Publication statusAccepted/In press - 2017 Nov 14

Fingerprint

Pylorus
Helicobacter pylori
Stomach Neoplasms
Gastritis
Rifabutin
Clarithromycin
Quinolones
Metronidazole
Helicobacter Infections
Therapeutics

Keywords

  • Clarithromycin
  • Fluoroquinolone
  • Gastric cancer
  • H. pylori
  • Metronidazole

ASJC Scopus subject areas

  • Gastroenterology

Cite this

World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. / Suzuki, Hidekazu; Mori, Hideki.

In: Journal of Gastroenterology, 14.11.2017, p. 1-8.

Research output: Contribution to journalArticle

@article{c0eca67e5de346c0a735ec2f6f83d0b6,
title = "World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat",
abstract = "Helicobacter pylori-associated gastritis leads to the development of gastric cancer. Kyoto global consensus report on H. pylori gastritis recommended H. pylori eradication therapy to prevent gastric cancer. To manage H. pylori infection, it is important to choose the appropriate regimen considering regional differences in resistance to clarithromycin and metronidazole. Quinolones and rifabutin-containing regimens are useful as third- and fourth-line rescue therapies.",
keywords = "Clarithromycin, Fluoroquinolone, Gastric cancer, H. pylori, Metronidazole",
author = "Hidekazu Suzuki and Hideki Mori",
year = "2017",
month = "11",
day = "14",
doi = "10.1007/s00535-017-1407-1",
language = "English",
pages = "1--8",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",

}

TY - JOUR

T1 - World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat

AU - Suzuki, Hidekazu

AU - Mori, Hideki

PY - 2017/11/14

Y1 - 2017/11/14

N2 - Helicobacter pylori-associated gastritis leads to the development of gastric cancer. Kyoto global consensus report on H. pylori gastritis recommended H. pylori eradication therapy to prevent gastric cancer. To manage H. pylori infection, it is important to choose the appropriate regimen considering regional differences in resistance to clarithromycin and metronidazole. Quinolones and rifabutin-containing regimens are useful as third- and fourth-line rescue therapies.

AB - Helicobacter pylori-associated gastritis leads to the development of gastric cancer. Kyoto global consensus report on H. pylori gastritis recommended H. pylori eradication therapy to prevent gastric cancer. To manage H. pylori infection, it is important to choose the appropriate regimen considering regional differences in resistance to clarithromycin and metronidazole. Quinolones and rifabutin-containing regimens are useful as third- and fourth-line rescue therapies.

KW - Clarithromycin

KW - Fluoroquinolone

KW - Gastric cancer

KW - H. pylori

KW - Metronidazole

UR - http://www.scopus.com/inward/record.url?scp=85033674013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033674013&partnerID=8YFLogxK

U2 - 10.1007/s00535-017-1407-1

DO - 10.1007/s00535-017-1407-1

M3 - Article

C2 - 29138921

AN - SCOPUS:85033674013

SP - 1

EP - 8

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

ER -